---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-341229"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2026-08-10T11:13:38+00:00"
generated_at: "2026-08-10T11:15:05.775074+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences Q2 2026 net loss $55.8M; JADE101 Phase 1 data positive, cash $461M

## Summary
- Q2 2026 net loss $55.8M vs $32.1M in Q2 2025; R&D $50.1M, G&A $8.9M.
- Cash, equivalents, investments $461.2M as of June 30, 2026; runway into Q4 2028 after $172.5M offering.
- JADE101 Phase 1: ~70% mean IgA reduction after single 700mg dose; supports every-12-week dosing; Phase 2 JUNIPER underway, Phase 3 expected H1 2027.
- JADE201 Phase 1 in rheumatoid arthritis dosing began; interim data 2027. JADE301 for dermatomyositis unveiled; Phase 1 healthy volunteers expected Q4 2026.
- Mark Eisner, M.D., appointed to board; company advancing pipeline.

## SEC filing metadata
- accession: 0001193125-26-341229
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2026-08-10T11:13:38+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/0001193125-26-341229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-341229
- JSON: https://secwatch.observer/filing/0001193125-26-341229.json
- Plain text: https://secwatch.observer/filing/0001193125-26-341229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.